Randox Plans to Release Eight New Biochip Panels for Evidence System in Coming Months | GenomeWeb

Boston — Fleshing out the menu for its Evidence biochip systems, Randox plans to launch eight new panels this month for applications such as drugs of abuse, cerebral disorders, colorectal cancer, and cardiovascular disease.

The availability of the new content-specific chips will greatly expand the Crumlin, UK-based company's current offering for its Evidence systems, and makes good on earlier promises by management to grow its biochip portfolio by this spring, (see BAN 12/14/2005).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.